Pomalyst (Pomalidomide) for amyloidosis

Overview
Pomalyst is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults and children with multiple myeloma who have received at least two prior therapies. Pomalyst is sometimes prescribed off-label to treat amyloidosis. Pomalyst is also referred to by its drug name, pomalidomide.

Pomalyst is used as a therapy for amyloidosis. Pomalyst is a member of a class of drugs called immunomodulators. Pomalyst is believed to work by blocking the growth of new blood vessels that supply nutrients to the abnormal plasma cells that produce amyloid proteins. Additionally, Pomalyst can stimulate the production of healthy immune cells that fight against abnormal plasma cells.

How do I take it?
Pomalyst is given orally as a capsule. It should be taken exactly as prescribed by the physician.

Side effects
The FDA-approved label for Pomalyst lists common side effects that include fatigue, weakness, anemia (low red blood cell count), constipation, nausea, diarrhea, difficulty breathing, upper respiratory tract infections, back pain, and fever.

Serious side effects listed for Pomalyst include blood toxicity, deep vein thrombosis, pulmonary embolism, dizziness and confusion, fetal harm, and nerve problems.

For more details about this treatment, visit:
Pomalyst — Bristol Myers Squibb
What Is Pomalyst? — Multiple Myeloma Research Foundation